|
Breast Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
We investigated whether GSTT1 ("null" allele), GSTM1 ("null"allele), GSTP1 (A313G), RFC1 (G80A), MTHFR (C677T), TS (2R/3R) polymorphisms were associated with toxicity and survival in patients with early breast cancer (EBC) treated with adjuvant chemotherapy (CT).
|
28747156 |
2017 |
|
Malignant neoplasm of breast
|
|
0.040 |
GeneticVariation
|
BEFREE |
We investigated whether GSTT1 ("null" allele), GSTM1 ("null"allele), GSTP1 (A313G), RFC1 (G80A), MTHFR (C677T), TS (2R/3R) polymorphisms were associated with toxicity and survival in patients with early breast cancer (EBC) treated with adjuvant chemotherapy (CT).
|
28747156 |
2017 |
|
Malignant neoplasm of breast
|
|
0.040 |
GeneticVariation
|
BEFREE |
Although the authors first determined whether genotypes of drug-metabolizing enzymes and transporters--glutathione S-transferase (GST) genes, GSTM1 positive/null, GSTT1 positive/null and GSTP1 A313G, methylenetetrahydrofolate reductase (MTHFR) C677T, reduced folate carrier 1 (RFC1) G80A, and breast cancer resistant protein (BCRP) C421A--were associated with hepatotoxicity for 24 patients, no significant difference was detected for genotype and allelic frequencies between the patients with and those without severe treatment-related hepatotoxicity.
|
20670164 |
2010 |
|
Breast Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Although the authors first determined whether genotypes of drug-metabolizing enzymes and transporters--glutathione S-transferase (GST) genes, GSTM1 positive/null, GSTT1 positive/null and GSTP1 A313G, methylenetetrahydrofolate reductase (MTHFR) C677T, reduced folate carrier 1 (RFC1) G80A, and breast cancer resistant protein (BCRP) C421A--were associated with hepatotoxicity for 24 patients, no significant difference was detected for genotype and allelic frequencies between the patients with and those without severe treatment-related hepatotoxicity.
|
20670164 |
2010 |
|
Breast Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Genetic polymorphisms of glutathione S-transferase (GST) genes including GSTT1 positive/null, GSTM1 positive/null, and GSTP1 A313G, and genes for reduced folate carrier 1 G80A (RFC1 G80A), methylenetetrahydrofolate reductase C677T (MTHFR C677T), and breast cancer resistant protein C421A (BCRP C421A) were determined for 26 patients by the polymerase chain reaction (PCR) method or by direct sequencing.
|
17180579 |
2007 |
|
Malignant neoplasm of breast
|
|
0.040 |
GeneticVariation
|
BEFREE |
Genetic polymorphisms of glutathione S-transferase (GST) genes including GSTT1 positive/null, GSTM1 positive/null, and GSTP1 A313G, and genes for reduced folate carrier 1 G80A (RFC1 G80A), methylenetetrahydrofolate reductase C677T (MTHFR C677T), and breast cancer resistant protein C421A (BCRP C421A) were determined for 26 patients by the polymerase chain reaction (PCR) method or by direct sequencing.
|
17180579 |
2007 |
|
Breast Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Trends in the association between urinary ITC and breast cancer were more consistent with homozygous deletion of GSTM1 or GSTT1, the AAgenotype of GSTP1 (A313G), or with the C allele of NADPH quinine oxidoreductase (C609T), although interactions were not statistically significant.
|
12873994 |
2003 |
|
Malignant neoplasm of breast
|
|
0.040 |
GeneticVariation
|
BEFREE |
Trends in the association between urinary ITC and breast cancer were more consistent with homozygous deletion of GSTM1 or GSTT1, the AAgenotype of GSTP1 (A313G), or with the C allele of NADPH quinine oxidoreductase (C609T), although interactions were not statistically significant.
|
12873994 |
2003 |
|
Bladder Neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
Combination of the high-risk genotypes (GSTM1 null + GSTT1 null + GSTP1 313 A/G or G/G) demonstrated further increase in the BC risk (OR = 6.64, 95 %CI = 3.63-12.16).
|
23054023 |
2013 |
|
Malignant neoplasm of urinary bladder
|
|
0.020 |
GeneticVariation
|
BEFREE |
Combination of the high-risk genotypes (GSTM1 null + GSTT1 null + GSTP1 313 A/G or G/G) demonstrated further increase in the BC risk (OR = 6.64, 95 %CI = 3.63-12.16).
|
23054023 |
2013 |
|
Carcinoma of bladder
|
|
0.020 |
GeneticVariation
|
BEFREE |
Combination of the high-risk genotypes (GSTM1 null + GSTT1 null + GSTP1 313 A/G or G/G) demonstrated further increase in the BC risk (OR = 6.64, 95 %CI = 3.63-12.16).
|
23054023 |
2013 |
|
Bladder Neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
We investigated the effect of the GSTM1 and GSTT1 null genotypes, and GSTP1 313 A/G polymorphism on bladder cancer susceptibility in a case control study of 121 bladder cancer patients, and 121 age- and sex-matched controls of the Turkish population.
|
11757669 |
2001 |
|
Malignant neoplasm of urinary bladder
|
|
0.020 |
GeneticVariation
|
BEFREE |
We investigated the effect of the GSTM1 and GSTT1 null genotypes, and GSTP1 313 A/G polymorphism on bladder cancer susceptibility in a case control study of 121 bladder cancer patients, and 121 age- and sex-matched controls of the Turkish population.
|
11757669 |
2001 |
|
Carcinoma of bladder
|
|
0.020 |
GeneticVariation
|
BEFREE |
We investigated the effect of the GSTM1 and GSTT1 null genotypes, and GSTP1 313 A/G polymorphism on bladder cancer susceptibility in a case control study of 121 bladder cancer patients, and 121 age- and sex-matched controls of the Turkish population.
|
11757669 |
2001 |
|
Alzheimer Disease, Late Onset
|
|
0.010 |
GeneticVariation
|
BEFREE |
We investigated the association of GSTM1 and GSTT1 null deletion and GSTP1 313 A/G polymorphisms and the risk of AD in an Iranian population.
|
29072550 |
2018 |
|
Coronary Artery Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
Logistic regression analysis of the data revealed the null genotype of GSTM1 and the GG genotype of the GSTP1 (313A/G) gene were associated with an approximately twofold enhanced risk of developing CAD, whereas GSTT1(-) plays a defensive role against CAD development in north Indians.
|
30039864 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
|
0.010 |
GeneticVariation
|
BEFREE |
This study aimed to evaluate whether GSTM1 and GSTT1 (presents or nulls), GSTP1 c.313A>G and NQO2 c.-102A>C polymorphisms, involved in xenobiotic detoxification pathways, alter outcomes of epithelial ovarian cancer (EOC) patients.
|
27586145 |
2016 |
|
Epithelial ovarian cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
This study aimed to evaluate whether GSTM1 and GSTT1 (presents or nulls), GSTP1 c.313A>G and NQO2 c.-102A>C polymorphisms, involved in xenobiotic detoxification pathways, alter outcomes of epithelial ovarian cancer (EOC) patients.
|
27586145 |
2016 |
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The GSTP1 A313G mutant variant was associated with a higher PFS (HR = 0.55, P = 0.001) and OS (HR = 0.60, P = 0.002) in the CRC group.
|
25677447 |
2015 |
|
Multiple Sclerosis
|
|
0.010 |
GeneticVariation
|
BEFREE |
No association with MS was observed in relation to the GSTM1 null genotype in Caucasian populations (OR = 1.229, 95 % CI 0.693-2.181, p = 0.481), nor with the GSTP1 A313G polymorphism (OR for G allele = 1.133, 95 % CI 0.903-1.421, p = 0.281).
|
26150166 |
2015 |
|
Non-Small Cell Lung Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our study suggested that the GSTP1 A313G and GSTM1 null/present polymorphisms could predict the treatment response of the platinum-based chemotherapy in NSCLC patients, especially in East-Asian patients.
|
24729086 |
2014 |
|
Osteoporosis
|
|
0.010 |
GeneticVariation
|
BEFREE |
The GSTT1 deletion was associated with a higher frequency of the NMPA to homozygous deletion (p = 0.008), GSTP1 + 313A > G with a minor risk of osteoporosis (p = 0.036), and patient age ≤ 154 months (p = 0.044) with the AA genotype.
|
24593045 |
2014 |
|
Cystic Fibrosis
|
|
0.010 |
GeneticVariation
|
BEFREE |
We analyzed CFTR mutations, polymorphisms (GSTM1 and GSTT1 deletions, GSTP1 + 313A > G, GCLC-129C > T, and GCLC-3506A > G) in modifier genes and CF clinical severity as assessed by 28 clinical and laboratory variables.
|
24593045 |
2014 |
|
Malignant Head and Neck Neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
The variables age ≥ 48 years, smoking and drinking can be predictors for head and neck cancer development; moreover, A313G GSTP1 polymorphism, GSTM1 and GSTT1 null genotypes can modulate the risk for this disease.
|
23661016 |
2013 |
|
Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
In this study we investigate the association of A313G and C341T GSTP1 polymorphisms, GSTM1 and GSTT1 null genotypes in the head and neck cancer development, interactions between these polymorphisms,the tumor histopathologic parameters and risk factors (smoking and drinking) were also evaluated in the case-control study.
|
23661016 |
2013 |